UTHR(United Therapeutics Corporation) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $1.69B | $1.94B | $2.33B | $2.88B | $3.18B |
| 毛利润 | $1.56B | $1.78B | $2.07B | $2.57B | $2.80B |
| 营业利润 | $555.90M | $979.70M | $1.18B | $1.38B | $1.49B |
| 净利润 | $475.80M | $727.30M | $984.80M | $1.20B | $1.33B |
| 经营现金流 | $598.20M | $802.50M | $978.00M | $1.33B | $1.56B |
| 自由现金流 | $477.40M | $663.70M | $747.60M | $1.08B | $1.04B |
| 摊薄每股收益 | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |